학술논문
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Cheng, Ying; Wang, Jie; Zhou, Caicun; Yao, Wenxiu; Wang, Qiming; Min, Xuhong; Chen, Gongyan; Xu, Xingxiang; Li, Xingya; Xu, Fei; Fang, Yong; Yang, Runxiang; Yu, Guohua; Gong, Youling; Zhao, Jun; Fan, Yun; Liu, Quan; Cao, Lejie; Yao, Yu; Liu, Yunpeng; Li, Xiaoling; Wu, Jingxun; He, Zhiyong; Lu, Kaihua; Jiang, Liyan; Hu, Chengping; Zhao, Wenhua; Yu, Huiqing; Zhao, Jian; Wu, Gang; Huang, Dingzhi; Chen, Chengshui; Ding, Cuimin; Zhang, Baihong; Wang, Xiuwen; Luo, Hui; Li, Baolan; Zhang, Shucai; Lu, Hong; Shi, Meiqi; Chen, Xi; Guo, Yubiao; Liu, Hailong; Liu, Jiwei; Gao, Hongjun; Hu, Sheng; Hong, Qunying; Li, Qi; Zhang, Ben; Shi, Wei; Zhang, Xiaojing
Source
In The Lancet Oncology June 2022 23(6):739-747
Subject
Language
ISSN
1470-2045